article
8 March 2021 | By Hannah Balfour (Drug Target Review)
Mark Mortenson, CSO of Clene Nanomedicine, discusses the use of proprietary gold nanocrystals as catalysts to prevent the progression of, and act as a treatment for, neurodegenerative disease.